|
SenzaGen had a busy program at SOT 2021. To highlight our expanding capabilities in in vitro skin toxicology, we took part in several activities and presented our novel assays for quantitative skin sensitizing potency assessment and medical device testing.
SOT 2021 recap |
|
|
|
 |
We are very pleased that the Danish pharmaceutical company Lundbeck has decided to test compounds with both GARD™air and GARD™skin. Using this combination of tests, Lundbeck aims to determine whether new development candidates have potential sensitizing properties:
"The introduction of new innovative assays such as the GARD tests is part of our commitment to constantly expand our expertise in safety testing", says Allan Dahl Rasmussen, Director of Regulatory Toxicology in Lundbeck.
Read more |
|
|
 |
RIFM aims to evaluate GARD™skin Dose-Response as they refine their understanding of fragrance ingredients:
“Identifying the dosage at which a fragrance may induce sensitization is a need that fragrance industry stakeholders have expressed for a long time", Mihwa Na, PhD, Senior Scientist at RIFM explains.
We look forward to this collaboration and to contributing to progress in terms of sustainability and ethics in testing.
Read more |
|
|
 |
It is an exciting time at SenzaGen as we are growing the team. Dr Tim Lindberg is newly on board to support our Nordic customers with 5 years of experience from in vitro assay development including the GARD technology, and a previous sales role in the biotech industry. Our new VP Operations Åsa Nyhlén is ready to scale up our testing capacity and our new Laboratory Scientist Per Alftrén will be a great addition to our highly specialized team offering GLP testing services.
Ask a question to our new specialists |
|
|
• Webinar: SOT 2021 Poster Presentations
April 14 @ 16.00 CEST | Register
• Webinar: Filling in data gaps in skin sensitizing potency assessment
May 27 @ 16.00 CEST | Info
|
|
|
|
%20Color%20RGB.png)
